Clinuvel Pharmaceuticals Ltd
OTC:CLVLY
Clinuvel Pharmaceuticals Ltd
OTC:CLVLY
Price:
7.6
USD
-3.31%
Market Closed
Market Cap:
$392m
Balance Sheet
Balance Sheet Decomposition
Clinuvel Pharmaceuticals Ltd
Clinuvel Pharmaceuticals Ltd
Balance Sheet Decomposition is not available for
Clinuvel Pharmaceuticals Ltd
Clinuvel Pharmaceuticals Ltd
Balance Sheet
Clinuvel Pharmaceuticals Ltd
Clinuvel Pharmaceuticals Ltd
Currency: AUD
| Jun-2002 | Jun-2003 | Jun-2004 | Jun-2005 | Jun-2006 | Jun-2007 | Jun-2008 | Jun-2009 | Jun-2010 | Jun-2011 | Jun-2012 | Jun-2013 | Jun-2014 | Jun-2015 | Jun-2016 | Jun-2017 | Jun-2018 | Jun-2019 | Jun-2020 | Jun-2021 | Jun-2022 | Jun-2023 | Jun-2024 | Jun-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||||||||||||||
| Cash & Cash Equivalents |
4
|
3
|
5
|
5
|
9
|
34
|
1
|
2
|
2
|
2
|
7
|
1
|
2
|
3
|
4
|
14
|
17
|
24
|
24
|
35
|
23
|
23
|
18
|
26
|
|
| Cash |
4
|
3
|
5
|
5
|
9
|
34
|
1
|
2
|
2
|
2
|
7
|
1
|
2
|
3
|
4
|
14
|
17
|
24
|
24
|
35
|
23
|
23
|
18
|
26
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
2
|
29
|
50
|
36
|
25
|
15
|
6
|
11
|
13
|
8
|
10
|
10
|
20
|
30
|
43
|
48
|
99
|
134
|
166
|
198
|
|
| Total Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
1
|
1
|
2
|
2
|
2
|
5
|
3
|
5
|
4
|
7
|
16
|
16
|
22
|
26
|
27
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
1
|
1
|
2
|
2
|
2
|
5
|
3
|
5
|
4
|
7
|
16
|
16
|
22
|
26
|
27
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Inventory |
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
2
|
1
|
3
|
2
|
10
|
11
|
9
|
|
| Other Current Assets |
0
|
0
|
0
|
0
|
2
|
3
|
2
|
3
|
2
|
1
|
2
|
1
|
1
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
3
|
|
| Total Current Assets |
4
|
3
|
6
|
5
|
14
|
65
|
53
|
41
|
29
|
20
|
16
|
16
|
17
|
14
|
20
|
28
|
42
|
61
|
75
|
103
|
141
|
190
|
222
|
263
|
|
| PP&E Net |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
2
|
3
|
3
|
3
|
8
|
7
|
|
| PP&E Gross |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
2
|
3
|
3
|
3
|
8
|
7
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
2
|
2
|
3
|
4
|
|
| Intangible Assets |
6
|
5
|
4
|
5
|
3
|
2
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Goodwill |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
4
|
3
|
0
|
1
|
1
|
1
|
|
| Other Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
11
N/A
|
8
-23%
|
10
+27%
|
10
-2%
|
17
+70%
|
68
+297%
|
55
-19%
|
42
-24%
|
30
-29%
|
20
-32%
|
16
-21%
|
16
-1%
|
17
+8%
|
14
-20%
|
20
+48%
|
29
+42%
|
43
+50%
|
62
+45%
|
82
+31%
|
109
+33%
|
144
+33%
|
194
+35%
|
231
+19%
|
272
+18%
|
|
| Liabilities | |||||||||||||||||||||||||
| Accounts Payable |
0
|
0
|
1
|
2
|
3
|
2
|
3
|
4
|
3
|
3
|
2
|
1
|
1
|
2
|
2
|
2
|
2
|
4
|
5
|
5
|
3
|
8
|
7
|
10
|
|
| Accrued Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
3
|
4
|
0
|
1
|
2
|
2
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
10
|
16
|
16
|
15
|
|
| Total Current Liabilities |
0
|
1
|
1
|
3
|
3
|
2
|
3
|
5
|
3
|
4
|
2
|
2
|
2
|
2
|
2
|
3
|
3
|
5
|
8
|
9
|
14
|
25
|
25
|
27
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
0
|
|
| Deferred Income Tax |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
4
|
3
|
2
|
3
|
|
| Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Liabilities |
0
N/A
|
1
+157%
|
1
+157%
|
3
+87%
|
3
+18%
|
2
-21%
|
3
+30%
|
5
+44%
|
3
-32%
|
4
+22%
|
2
-37%
|
2
-16%
|
2
-13%
|
2
+40%
|
2
-3%
|
3
+38%
|
3
+8%
|
5
+48%
|
9
+83%
|
10
+4%
|
18
+87%
|
29
+58%
|
28
-3%
|
31
+10%
|
|
| Equity | |||||||||||||||||||||||||
| Common Stock |
15
|
17
|
25
|
35
|
53
|
113
|
113
|
113
|
113
|
113
|
119
|
127
|
134
|
138
|
147
|
148
|
149
|
151
|
152
|
152
|
152
|
152
|
169
|
169
|
|
| Retained Earnings |
5
|
9
|
17
|
28
|
39
|
47
|
63
|
76
|
87
|
97
|
106
|
113
|
118
|
128
|
129
|
123
|
110
|
95
|
80
|
54
|
28
|
10
|
31
|
66
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
2
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
0
|
1
|
2
|
3
|
3
|
5
|
|
| Total Equity |
10
N/A
|
8
-27%
|
9
+18%
|
7
-16%
|
14
+88%
|
65
+367%
|
52
-21%
|
37
-29%
|
26
-29%
|
16
-38%
|
14
-17%
|
14
+1%
|
15
+11%
|
11
-27%
|
18
+59%
|
25
+43%
|
39
+55%
|
57
+45%
|
72
+26%
|
99
+37%
|
126
+27%
|
165
+31%
|
203
+23%
|
241
+19%
|
|
| Total Liabilities & Equity |
11
N/A
|
8
-23%
|
10
+27%
|
10
-2%
|
17
+70%
|
68
+297%
|
55
-19%
|
42
-24%
|
30
-29%
|
20
-32%
|
16
-21%
|
16
-1%
|
17
+8%
|
14
-20%
|
20
+48%
|
29
+42%
|
43
+50%
|
62
+45%
|
82
+31%
|
109
+33%
|
144
+33%
|
194
+35%
|
231
+19%
|
272
+18%
|
|
| Shares Outstanding | |||||||||||||||||||||||||
| Common Shares Outstanding |
9
|
10
|
12
|
13
|
19
|
30
|
30
|
30
|
30
|
30
|
35
|
38
|
42
|
45
|
47
|
48
|
48
|
49
|
49
|
49
|
49
|
49
|
50
|
50
|
|
Switch to:
Switch to:
See Also
Discover More
